Pharmaceutical composition for treating lysosomal storage disease
AssigneeOsaka Unversity
InventorsKeiichi Ozono, Takanobu Otomo, Norio Sakai
Life of this patent
Estimating the term…
Abstract
The purpose of the present invention is to provide, in a simple and also inexpensive manner, a pharmaceutical composition which comprises a plurality of lysosomal enzymes and is effective in treating lysosomal storage disease caused by a deficiency in a plurality of lysosomal enzymes. Provided is a pharmaceutical composition for treating lysosomal storage disease, the composition comprising as an active ingredient a lysosomal enzyme group obtained from cells derived from a subject who does not suffer from lysosomal storage disease.
Claims11
-11. (canceled)
A pharmaceutical composition for treating mucolipidosis type II or type III, comprising a group of purified lysosomal enzymes as an active ingredient, wherein the group of lysosomal enzymes is obtained by culturing a cell, and the group of purified lysosomal enzymes comprises at least α-mannosidase, α-fucosidase, α-galactosidase, α-glucosidase, β-galactosidase, β-glucosidase, β-hexosaminidase, β-glucuronidase, galactocerebrosidase, and cathepsin.
A process for producing a pharmaceutical composition for treating mucolipidosis type II or type III, comprising a group of purified lysosomal enzymes as an active ingredient, wherein the group of purified lysosomal enzymes comprises at least α-mannosidase, α-fucosidase, α-galactosidase, α-glucosidase, β-galactosidase, β-glucosidase, β-hexosaminidase, β-glucuronidase, galactocerebrosidase, and cathepsin, the process comprises obtaining the group of lysosomal enzymes by a method comprising the following steps:
- adding to a cell one or more reagents selected from the group consisting of amphiphilic amines, lysosome-tropic amines, ionophores, and V-ATPase inhibitors, followed by culturing;
- collecting a culture supernatant;
- and
- purifying the obtained culture supernatant.
Dependencies are inferred from the claim text.